Vol. 4 No. 6 (2024)
Reimbursement Reviews

Cannabidiol (Epidiolex)

Published June 26, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cannabidiol (Epidiolex), 100 mg/mL, oral solution
  • Indication : Use as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 2 years of age and older.